



## Pixium Vision announces the release of its 2014 Interim Financial Report

**Paris, France. July 30<sup>th</sup>, 2014. 7:30 CET** – Pixium Vision (FR0011950641 – PIX eligible to PEA-PME), a company developing innovative Vision Restoration Systems (VRS) to allow patients who have lost their sight to lead more independent lives, announces today that it has released its 2014 interim financial report as at June 30<sup>th</sup> 2014. The report has been filed with the Autorité des marchés financiers in accordance with the regulated information guidelines.

The 2014 Interim Financial Report has been made available on the company's website, <http://www.pixium-vision.com>, in the section Financial Reports and Documents under the Investors tab.

### About Pixium Vision

Pixium Vision is developing innovative Vision Restoration Systems (VRS) that aim to significantly improve the independence, mobility and quality of life of patients who have lost their sight. The Company intends to harness the rapid advances being made in visual processing, microelectronics, optoelectronics, and intelligent software algorithms to develop systems that for blind people could ultimately provide vision approaching that of a normal healthy eye.

Pixium Vision is developing two VRS platforms:

- **IRIS<sup>®</sup>**: Clinical trials are currently underway with IRIS<sup>®</sup> in several centers in Europe with the goal of applying for CE Mark. Commercialization of IRIS<sup>®</sup> is expected to begin in 2015, subject to the obtaining of the CE Mark. Pixium Vision will continue to improve the performance of the IRIS<sup>®</sup> VRS notably through the development of new algorithms and software.
- **PRIMA**: Currently in preclinical development. The Company plans to begin clinical trials of PRIMA in Europe in 2016.

Pixium Vision was created in 2011 in Paris as a result of combined research, by the Vision Institute, the Pierre et Marie Curie University (UPMC), as well as the collaborative work of several European and American teams from prestigious academic and technological institutions, including Stanford University (USA).

**PIX**  
**LISTED**  
**EURONEXT**

Pixium Vision is an ISO 13485 certified company.  
Pixium Vision is listed on Euronext (Compartment C) in Paris.  
ISIN: FR0011950641; ticker: PIX

*IRIS<sup>®</sup>* is a trademark of Pixium-Vision SA

For more information, please visit [www.pixium-vision.com](http://www.pixium-vision.com)

### Contacts

**Pixium Vision**  
Pierre Kemula, CFO  
[contact@pixium-vision.com](mailto:contact@pixium-vision.com)  
+33 1 76 21 47 30

**Investors Relations / Press Relations**  
**Citigate Dewe Rogerson**  
Lucie Larguier – Laurence Bault (Paris)  
Mark Swallow – David Dible (Londres)  
[pixium-vision@citigatefr.com](mailto:pixium-vision@citigatefr.com) / [pixium-vision@citigatedr.co.uk](mailto:pixium-vision@citigatedr.co.uk)  
+33 1 53 32 84 78 / +44 20 7282 2948